An observational study of 134,000 adults suggests a potential link between GLP-1 medications and reduced fracture risk, though researchers emphasize the findings are not definitive proof.
Key facts
- •The study examined data from 134,000 American adults aged 50-90 with type 2 diabetes.
- •Participants taking GLP-1 medications showed a 21% lower risk of fragility fractures over three years compared to those on DPP-4 inhibitors.
- •The most significant fracture reductions were noted in the hip, femur, and spine.
- •Fragility fractures are defined as breaks occurring from low-energy events like falls that would not typically break healthy bone.
- •Researchers are currently conducting further studies to determine if a direct causal relationship exists between GLP-1 drugs and bone health.
A new observational study suggests that adults with type 2 diabetes taking GLP-1 medications may have a lower risk of fragility fractures. Researchers analyzed health data from approximately 134,000 American adults aged 50 to 90. The findings indicated a 21% lower risk of such fractures over a three-year period compared to those taking DPP-4 inhibitors, with the most significant reductions observed in hip and femur fractures.
By the numbers
Study Limitations and Expert Perspective
While the results are considered an important signal, researchers noted that the study is observational and cannot definitively prove that GLP-1 drugs cause the reduction in fracture risk. Dr. Christopher D. Hamad, the study's primary author, stated that further translational studies are required to investigate the underlying mechanisms, such as how these medications might influence bone cell balance and inflammation.
Diabetes and Bone Health
Medical experts not involved in the study highlighted that type 2 diabetes can negatively impact bone strength and turnover, often in ways that standard DEXA scans fail to detect. Additionally, factors such as neuropathy and vision issues associated with diabetes may increase the risk of falls. Physicians emphasized that because patients may experience weight loss or improved diabetes control while on GLP-1s, it remains unclear if the medication itself or these secondary factors contribute to the observed lower fracture risk.
Advertisement
This article was independently rewritten by ManyPress editorial AI from reporting originally published by Healthline.
